Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glibenclamide treatment for Cantú syndrome
NL-OMON54600Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of glibenclamide in Cantú syndrome, sponsored by Amsterdam University Medical Center. Primary endpoint: Mean change in number of hair follicles per cm2. Started Jan 2023; status: recruiting.
02
Drugs
glibenclamide
03
Conditions
Cantú syndrome
Beyond the preview
Go deeper on NL-OMON54600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54600.